不同抗凝方法对缺血性脑卒中患者血小板表面及血浆内GMP-140和IL-6的影响

目的检测缺血性脑卒中患者不同药物抗凝治疗前后血小板表面GMP-140分子数、血浆GMP-140和白介素-6(IL-6)含量的变化,探讨葛根素及噻氯匹定对GMP-140及IL-6的影响。方法用放射免疫法检测65例脑血栓形成(缺血性脑卒中)患者、25例短暂性脑缺血发作(TIA)患者和30例健康志愿者血小板表面GMP-140分子数、血浆GMP-140和白介素-6(IL-6)的含量,将65例缺血性卒中患者随机分成葛根素组(35例)及噻氯匹定组(30例)并予相应治疗,观察治疗4周后血小板表面GMP-140分子数、血浆GMP-140和白介素-6(IL-6)含量的变化。结果与健康人及TIA组比较,脑血栓形成患者血小板表面GMP-140分子数、血浆GMP-140和IL-6水平明显升高;治疗4周后葛根素组及噻氯匹定组上述测定值均显著低于治疗前水平(P<0.05,P<0.01),而治疗后2组间上述指标比较无显著性差异。结论血小板活化、炎症反应物的异常在缺血性脑卒中的发生发展过程中起着重要的作用,早期应用葛根素及噻氯匹定具有相同的抗凝效果,对预防缺血性脑卒中的发生和发展有重要的临床意义。

Influence of different anticoagulant methods on GMP-140 and IL-6 on platelet surface and in plasma in patients with cerebral arterial thrombosis

Objective It is to measure the change of GMP-140 molecule number on platelet surface and the contents of plasma GMP-140 and IL-6 in patients with cerebral arterial thrombosis before and after treatment with different anticoagulant and to study the influence of puerarin and Ticlopidine on GMP-140 and IL-6. Methods GMP-140 molecule number on platelet surface and the contents of plasma GMP140 and IL-6 in 65 cases of cerebral arterial thrombosis, 25 cases of TIA and 30 cases of healthy volunteer were detected with radioimmunoassay (RIA). 65 patients with cerebral arterial thrombosis were randomly divided into puerarin groups (35 cases) and Ticlopidine group (30 cases) and treated with corresponding medicine. The same indexes were detected after four weeks treatment. Results GMP-140 molecule number on platelet surface and the contents of plasma GMP-140 and IL-6 in patients with cerebral arterial thrombosis were obviously higher than those in TIA patients or healthy people. After four weeks treatment, the above mentioned parameters in puerarin group and Ticlopidine group were significantly lower than those before treatment (P<0.05 or P<0.01), but there was no significant difference between the two groups. Conclusion Platelet activation and inflammatory reactant abnormality play important roles during the occurrence and development of cerebral arterial thrombosis. Early treatment with puerarin or Ticlopidine has the same anticoagulant effect and has great importance in preventing the occurrence and development of cerebral arterial thrombosis.